Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-04 4:39 pm Purchase |
2024-04-02 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,951,463 19.200% |
2,124 (+0.02%) |
Filing History |
| 2024-03-28 4:28 pm Purchase |
2024-03-26 | 13D | Q32 Bio Inc. QTTB |
ORBIMED ADVISORS LLC | 2,252,987 18.900% |
2,252,987 (New Position) |
Filing History |
| 2024-03-22 4:59 pm Unchanged |
2024-03-21 | 13D | Compass Therapeutics, Inc. CMPX |
ORBIMED ADVISORS LLC | 18,791,422 13.700% |
0 (Unchanged) |
Filing History |
| 2024-03-21 4:31 pm Unchanged |
2024-03-19 | 13D | Adicet Bio, Inc. ACET |
ORBIMED ADVISORS LLC | 9,772,598 11.900% |
0 (Unchanged) |
Filing History |
| 2024-03-08 4:34 pm Sale |
2024-03-06 | 13D | NextCure, Inc. NXTC |
ORBIMED ADVISORS LLC | 1,268,013 4.500% |
-1,443,000 (-53.23%) |
Filing History |
| 2024-02-21 4:11 pm Unchanged |
2024-02-16 | 13D | Kinnate Biopharma Inc. KNTE |
ORBIMED ADVISORS LLC | 7,559,729 16.100% |
0 (Unchanged) |
Filing History |
| 2024-02-14 7:45 pm Sale |
2023-12-31 | 13G | ALX Oncology Holdings Inc. ALXO |
ORBIMED ADVISORS LLC | 2,255,000 4.500% |
-11,000 (-0.49%) |
Filing History |
| 2024-02-14 7:41 pm Purchase |
2023-12-31 | 13G | InspireMD, Inc. NSPR |
ORBIMED ADVISORS LLC | 2,133,405 9.900% |
2,133,405 (New Position) |
Filing History |
| 2024-02-14 7:36 pm Purchase |
2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 11,494,437 6.700% |
1,165,788 (+11.29%) |
Filing History |
| 2024-02-14 7:31 pm Purchase |
2023-12-31 | 13G | Verastem, Inc. VSTM |
ORBIMED ADVISORS LLC | 1,529,115 6.100% |
1,529,115 (New Position) |
Filing History |
| 2024-02-14 7:28 pm Sale |
2023-12-31 | 13G | SI-BONE, Inc. SIBN |
ORBIMED ADVISORS LLC | 2,144,631 5.300% |
-1,056,469 (-33.00%) |
Filing History |
| 2024-02-14 7:21 pm Purchase |
2023-12-31 | 13G | Scholar Rock Holding Corporation SRRK |
ORBIMED ADVISORS LLC | 2,960,000 4.100% |
2,960,000 (New Position) |
Filing History |
| 2024-02-14 7:11 pm Sale |
2023-12-31 | 13G | Protara Therapeutics, Inc. TARA |
ORBIMED ADVISORS LLC | 0 0.000% |
-671,741 (Position Closed) |
Filing History |
| 2024-02-14 7:00 pm Sale |
2023-12-31 | 13G | NeuroPace, Inc. NPCE |
ORBIMED ADVISORS LLC | 4,003,967 15.200% |
-8,314 (-0.21%) |
Filing History |
| 2024-02-14 6:55 pm Sale |
2023-12-31 | 13G | Mersana Therapeutics, Inc. MRSN |
ORBIMED ADVISORS LLC | 0 0.000% |
-7,082,837 (Position Closed) |
Filing History |
| 2024-02-14 6:51 pm Sale |
2023-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 0 0.000% |
-10,378,591 (Position Closed) |
Filing History |
| 2024-02-14 6:47 pm Sale |
2023-12-31 | 13G | Kezar Life Sciences, Inc. KZR |
ORBIMED ADVISORS LLC | 192,700 2.700% |
-156,812 (-44.87%) |
Filing History |
| 2024-02-14 6:42 pm Purchase |
2023-12-31 | 13G | Elevation Oncology, Inc. ELEV |
ORBIMED ADVISORS LLC | 3,000,000 6.800% |
3,000,000 (New Position) |
Filing History |
| 2024-02-14 6:36 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 1,667,360 2.500% |
-1,529,516 (-47.84%) |
Filing History |
| 2024-02-14 6:30 pm Sale |
2023-12-31 | 13G | Applied Therapeutics, Inc. APLT |
ORBIMED ADVISORS LLC | 0 0.000% |
-7,300,921 (Position Closed) |
Filing History |